A Rare but Treatable Disease: Therapeutic Considerations for Hairy Cell Leukemia

Published: Wednesday, Jul 10, 2019
 Martin S. Tallman, MD

Martin S. Tallman, MD
While uncommon, the prognosis for hairy cell leukemia (HCL) is quite favorable, explains Martin S. Tallman, MD, adding that most patients respond to the standard of care, cladribine, with relapse rates between 25% and 35%.

However, as the biology of HCL continues to be further understood, markers such as BRAF mutations has opened the door to new therapeutic strategies for patients.

In an interview with OncLive, Tallman, c
hief of Leukemia Service, Cassidy Family Endowed Faculty Chair, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the biology, prognosis, and current treatment options available in HCL.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
2nd Annual Live Medical Crossfire®: Hematologic Malignancies OnlineSep 28, 20198.0
Medical Crossfire®: BiTE Technology Around the Globe: Improving Outcomes for Patients With Acute Lymphoblastic LeukemiaSep 28, 20192.0
Publication Bottom Border
Border Publication